===Xenon Pharma (XENE) : Phase 3 X-TOLE2 azetukalner trial in focal onset seizures meets primary and key secondary endpoints

 

Xenon reports topline data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS). Azetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.

• X-TOLE2 results showed strong efficacy and favorable safety profile for azetukalner in focal onset seizures.
• Xenon plans to submit a U.S. FDA NDA for azetukalner in the third quarter of 2026.